296 related articles for article (PubMed ID: 15516973)
1. Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12.
Teramoto H; Castellone MD; Malek RL; Letwin N; Frank B; Gutkind JS; Lee NH
Oncogene; 2005 Jan; 24(3):489-501. PubMed ID: 15516973
[TBL] [Abstract][Full Text] [Related]
2. Identification of H-Ras, RhoA, Rac1 and Cdc42 responsive genes.
Teramoto H; Malek RL; Behbahani B; Castellone MD; Lee NH; Gutkind JS
Oncogene; 2003 May; 22(17):2689-97. PubMed ID: 12730683
[TBL] [Abstract][Full Text] [Related]
3. Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells.
Chambers AF; Behrend EI; Wilson SM; Denhardt DT
Anticancer Res; 1992; 12(1):43-7. PubMed ID: 1567180
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer.
Zhu Y; Denhardt DT; Cao H; Sutphin PD; Koong AC; Giaccia AJ; Le QT
Oncogene; 2005 Sep; 24(43):6555-63. PubMed ID: 16007184
[TBL] [Abstract][Full Text] [Related]
5. Ornithine decarboxylase induction in transformation by H-Ras and RhoA.
Shantz LM; Pegg AE
Cancer Res; 1998 Jul; 58(13):2748-53. PubMed ID: 9661886
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic Ras-mediated downregulation of Clast1/LR8 is involved in Ras-mediated neoplastic transformation and tumorigenesis in NIH3T3 cells.
Ryu SH; Kim KH; Kim HB; Kim MH; Kim NH; Kang Y; Hyun JW; Seo HJ; Jun JY; You HJ
Cancer Sci; 2010 Sep; 101(9):1990-6. PubMed ID: 20550525
[TBL] [Abstract][Full Text] [Related]
7. Vav transformation requires activation of multiple GTPases and regulation of gene expression.
Palmby TR; Abe K; Karnoub AE; Der CJ
Mol Cancer Res; 2004 Dec; 2(12):702-11. PubMed ID: 15634759
[TBL] [Abstract][Full Text] [Related]
8. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA.
Behrend EI; Craig AM; Wilson SM; Denhardt DT; Chambers AF
Cancer Res; 1994 Feb; 54(3):832-7. PubMed ID: 8306346
[TBL] [Abstract][Full Text] [Related]
9. Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth.
Medico E; Gentile A; Lo Celso C; Williams TA; Gambarotta G; Trusolino L; Comoglio PM
Cancer Res; 2001 Aug; 61(15):5861-8. PubMed ID: 11479227
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling by DNA microarray analysis in mouse embryonic fibroblasts transformed by rasV12 mutated protein and the E1A oncogene.
Vasseur S; Malicet C; Calvo EL; Labrie C; Berthezene P; Dagorn JC; Iovanna JL
Mol Cancer; 2003 Mar; 2():19. PubMed ID: 12685932
[TBL] [Abstract][Full Text] [Related]
11. Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells.
Castellone MD; Celetti A; Guarino V; Cirafici AM; Basolo F; Giannini R; Medico E; Kruhoffer M; Orntoft TF; Curcio F; Fusco A; Melillo RM; Santoro M
Oncogene; 2004 Mar; 23(12):2188-96. PubMed ID: 14981541
[TBL] [Abstract][Full Text] [Related]
12. Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells.
Mi Z; Guo H; Wai PY; Gao C; Kuo PC
Carcinogenesis; 2006 Jun; 27(6):1134-45. PubMed ID: 16474180
[TBL] [Abstract][Full Text] [Related]
13. Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells.
Lee JL; Wang MJ; Sudhir PR; Chen GD; Chi CW; Chen JY
Cancer Res; 2007 Mar; 67(5):2089-97. PubMed ID: 17332338
[TBL] [Abstract][Full Text] [Related]
14. Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration.
Zohar R; Suzuki N; Suzuki K; Arora P; Glogauer M; McCulloch CA; Sodek J
J Cell Physiol; 2000 Jul; 184(1):118-30. PubMed ID: 10825241
[TBL] [Abstract][Full Text] [Related]
15. Transforming JB6 cells exhibit enhanced integrin-mediated adhesion to osteopontin.
Chang PL; Chambers AF
J Cell Biochem; 2000 Apr; 78(1):8-23. PubMed ID: 10797562
[TBL] [Abstract][Full Text] [Related]
16. Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis.
Wai PY; Mi Z; Guo H; Sarraf-Yazdi S; Gao C; Wei J; Marroquin CE; Clary B; Kuo PC
Carcinogenesis; 2005 Apr; 26(4):741-51. PubMed ID: 15661802
[TBL] [Abstract][Full Text] [Related]
17. Global gene expression profiling unveils S100A8/A9 as candidate markers in H-ras-mediated human breast epithelial cell invasion.
Moon A; Yong HY; Song JI; Cukovic D; Salagrama S; Kaplan D; Putt D; Kim H; Dombkowski A; Kim HR
Mol Cancer Res; 2008 Oct; 6(10):1544-53. PubMed ID: 18922970
[TBL] [Abstract][Full Text] [Related]
18. A small interfering RNA targeting osteopontin as gastric cancer therapeutics.
Gong M; Lu Z; Fang G; Bi J; Xue X
Cancer Lett; 2008 Dec; 272(1):148-59. PubMed ID: 18694621
[TBL] [Abstract][Full Text] [Related]
19. Cloning of hamster osteopontin and expression distribution in normal tissues and experimentally induced oral squamous-cell carcinoma.
Jin H; Valverde P; Chen J
Arch Oral Biol; 2006 Mar; 51(3):236-45. PubMed ID: 16095557
[TBL] [Abstract][Full Text] [Related]
20. Expression of antisense osteopontin RNA inhibits tumor promoter-induced neoplastic transformation of mouse JB6 epidermal cells.
Su L; Mukherjee AB; Mukherjee BB
Oncogene; 1995 Jun; 10(11):2163-9. PubMed ID: 7784060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
